Gold Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$761K Hold
12,542
0.24% 83
2025
Q4
$677K Buy
12,542
+53
+0.4% +$2.55K 0.22% 84
2025
Q3
$563K Buy
12,489
+42
+0.3% +$1.96K 0.19% 87
2025
Q2
$582K Hold
12,447
0.22% 84
2025
Q1
$759K Sell
12,447
-325
-3% -$18.9K 0.32% 80
2024
Q4
$722K Hold
12,772
0.3% 81
2024
Q3
$654K Buy
12,772
+21
+0.2% +$985 0.27% 81
2024
Q2
$530K Sell
12,751
-1,090
-8% -$48.8K 0.22% 87
2024
Q1
$751K Buy
13,841
+262
+2% +$13.3K 0.3% 80
2023
Q4
$697K Buy
+13,579
New +$713K 0.3% 80

Other funds holding BMY

Gold Investment Management's BMY Position: Q1 2026 in Review

Gold Investment Management held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 12,542 shares worth $761K. The position accounts for 0.24% of the portfolio, ranked #83.

Gold Investment Management first reported a position in BMY in Q4 2023 and has held it in 10 quarters since. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Gold Investment Management held 12,542 shares of Bristol-Myers Squibb worth $761K as of Q1 2026.
  • Gold Investment Management left its Bristol-Myers Squibb share count unchanged in Q1 2026.
  • Bristol-Myers Squibb made up 0.24% of Gold Investment Management's portfolio in Q1 2026, its #83 holding.
  • Gold Investment Management first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 10 quarters since.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Gold Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.